Do we need a different set of response assessment criteria for tumor immunotherapy?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19934296.
- Also identified by DOI 10.1158/1078-0432.CCR-09-2376.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor shrinkage induced by tumor immunotherapy may be preceded by inflammatory changes. This confounds the assessment of response rates to tumor immunotherapy. In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria.
Medical subject headings
- Immunotherapy
- Neoplasms
- Treatment Outcome